661 related articles for article (PubMed ID: 22824809)
1. Expression of cancer stem cell markers in pancreatic intraepithelial neoplasias and pancreatic ductal adenocarcinomas.
Kure S; Matsuda Y; Hagio M; Ueda J; Naito Z; Ishiwata T
Int J Oncol; 2012 Oct; 41(4):1314-24. PubMed ID: 22824809
[TBL] [Abstract][Full Text] [Related]
2. Co-Expression of Cancer Stem Cell Markers Corresponds to a Pro-Tumorigenic Expression Profile in Pancreatic Adenocarcinoma.
Skoda J; Hermanova M; Loja T; Nemec P; Neradil J; Karasek P; Veselska R
PLoS One; 2016; 11(7):e0159255. PubMed ID: 27414409
[TBL] [Abstract][Full Text] [Related]
3. Epithelial mesenchymal transition correlates with CD24+CD44+ and CD133+ cells in pancreatic cancer.
Zhang Y; Wei J; Wang H; Xue X; An Y; Tang D; Yuan Z; Wang F; Wu J; Zhang J; Miao Y
Oncol Rep; 2012 May; 27(5):1599-605. PubMed ID: 22322379
[TBL] [Abstract][Full Text] [Related]
4. Significance of Expression of Cancer Stem Cell Markers CD133 and Nestin in Pancreatic Intraepithelial Carcinoma-invasive Adenocarcinoma Sequence.
Alshenawy HA
Appl Immunohistochem Mol Morphol; 2020 Mar; 28(3):205-212. PubMed ID: 32197003
[TBL] [Abstract][Full Text] [Related]
5. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer.
Kapucuoğlu N; Bozkurt KK; Başpınar Ş; Koçer M; Eroğlu HE; Akdeniz R; Akçil M
Pathol Res Pract; 2015 Oct; 211(10):740-7. PubMed ID: 26298632
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity.
Currie MJ; Beardsley BE; Harris GC; Gunningham SP; Dachs GU; Dijkstra B; Morrin HR; Wells JE; Robinson BA
Hum Pathol; 2013 Mar; 44(3):402-11. PubMed ID: 23036368
[TBL] [Abstract][Full Text] [Related]
7. Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis.
Durko L; Wlodarski W; Stasikowska-Kanicka O; Wagrowska-Danilewicz M; Danilewicz M; Hogendorf P; Strzelczyk J; Malecka-Panas E
Dis Markers; 2017; 2017():3276806. PubMed ID: 28659655
[TBL] [Abstract][Full Text] [Related]
8. CD49f-positive cell population efficiently enriches colon cancer-initiating cells.
Haraguchi N; Ishii H; Mimori K; Ohta K; Uemura M; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Doki Y; Mori M
Int J Oncol; 2013 Aug; 43(2):425-30. PubMed ID: 23708747
[TBL] [Abstract][Full Text] [Related]
9. Coexpression of CD44-positive/CD133-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma.
Hou YC; Chao YJ; Tung HL; Wang HC; Shan YS
Cancer; 2014 Sep; 120(17):2766-77. PubMed ID: 24839953
[TBL] [Abstract][Full Text] [Related]
10. Nestin and other putative cancer stem cell markers in pancreatic cancer.
Matsuda Y; Kure S; Ishiwata T
Med Mol Morphol; 2012 Jun; 45(2):59-65. PubMed ID: 22718289
[TBL] [Abstract][Full Text] [Related]
11. Expression of the stem cell markers CD133 and nestin in pancreatic ductal adenocarcinoma and clinical relevance.
Kim HS; Yoo SY; Kim KT; Park JT; Kim HJ; Kim JC
Int J Clin Exp Pathol; 2012; 5(8):754-61. PubMed ID: 23071857
[TBL] [Abstract][Full Text] [Related]
12. Annexin A10 is a candidate marker associated with the progression of pancreatic precursor lesions to adenocarcinoma.
Zhu J; Wu J; Pei X; Tan Z; Shi J; Lubman DM
PLoS One; 2017; 12(4):e0175039. PubMed ID: 28369074
[TBL] [Abstract][Full Text] [Related]
13. Putative stem cell markers in non-small-cell lung cancer: a clinicopathologic characterization.
Sterlacci W; Savic S; Fiegl M; Obermann E; Tzankov A
J Thorac Oncol; 2014 Jan; 9(1):41-9. PubMed ID: 24346092
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of cancer stem cell markers in normal pancreas and pancreatic ductal adenocarcinoma.
Vizio B; Mauri FA; Prati A; Trivedi P; Giacobino A; Novarino A; Satolli MA; Ciuffreda L; Camandona M; Gasparri G; Bellone G
Oncol Rep; 2012 Jan; 27(1):69-76. PubMed ID: 21922151
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of fibroblast growth factor receptor 4 in high-grade pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma.
Motoda N; Matsuda Y; Onda M; Ishiwata T; Uchida E; Naito Z
Int J Oncol; 2011 Jan; 38(1):133-43. PubMed ID: 21109934
[TBL] [Abstract][Full Text] [Related]
16. Characterization of cancer stem cells from different grades of human colorectal cancer.
Manhas J; Bhattacharya A; Agrawal SK; Gupta B; Das P; Deo SV; Pal S; Sen S
Tumour Biol; 2016 Oct; 37(10):14069-14081. PubMed ID: 27507615
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1α in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Wang Z; Shi Q; Wang Z; Gu Y; Shen Y; Sun M; Deng M; Zhang H; Fang J; Zhang S; Xie F
Pathol Res Pract; 2011 Aug; 207(8):505-13. PubMed ID: 21802218
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic cancer stem cells: features and detection methods.
Ishiwata T; Matsuda Y; Yoshimura H; Sasaki N; Ishiwata S; Ishikawa N; Takubo K; Arai T; Aida J
Pathol Oncol Res; 2018 Oct; 24(4):797-805. PubMed ID: 29948612
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma.
Askan G; Sahin IH; Chou JF; Yavas A; Capanu M; Iacobuzio-Donahue CA; Basturk O; O'Reilly EM
BMC Cancer; 2021 Apr; 21(1):385. PubMed ID: 33836674
[TBL] [Abstract][Full Text] [Related]
20. CD24 and S100A4 expression in resectable pancreatic cancers with earlier disease recurrence and poor survival.
Lee SH; Kim H; Hwang JH; Shin E; Lee HS; Hwang DW; Cho JY; Yoon YS; Han HS; Cha BH
Pancreas; 2014 Apr; 43(3):380-8. PubMed ID: 24622067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
